Microbix Biosystems Inc. is a Canada-based company. The Company is engaged in the development, manufacturing and distribution of cell-based products and technology and, provision of facility, technical and production personnel for contract research and development. Sequent Biotechnologies Inc. is the Company’s wholly owned subsidiary. In September 2008, the Company announced that it has divested its urokinase business to Microbix Biosystems Inc. Through this transaction, Microbix has acquired the remaining urokinase inventory and related assets and has assumed full responsibility for ongoing commercial and regulatory activities associated with the product. Urokinase is an United States Food and Drug association (FDA)-approved thrombolytic, or clot-dissolving agent, indicated for the treatment of acute massive pulmonary embolism.
